Attention Investors: Note: The depositories (CDSL/NSDL), in coordination with SEBI, have upgraded their investor mobile applications to provide a consolidated view of investors’ holdings in securities markets. CDSL: MyEasiApp | NSDL: Speede App Beware of fraudulent Calls, SMS, Emails, WhatsApp & Telegram messages assuring high returns and / or enticing you to invest money in the name of Aditya Birla Money by installing fake App from spurious links. You can download our Elevate App only from Google Play Store or Apple App Store or login to Elevate Web portal. Click Here to know more.
Experience finance made simple on the new ABCD app!
Scan to Download the App
One stop solution for all stock market enthusiasts
Whatsapp us!! We are Available.
Send HI on 8828800038
For Broking services
Call Toll Free Number :
1800-270-7000
( Mon - Fri: 9AM - 11PM )
( Sat & Sun: 9AM - 09PM )
Call N Trade
Call :
1800-108-9999
( 9AM to 11:30PM /11:55PM )
Acquire & service self-trading online & offline clients. Archive large-scale business success with the entire product range offered by us.
Earn while you refer client. No need to set up your own infrastructure.
Join our referral program, earn rewards when friends and family open accounts & transact. Spread the word, multiply your earnings!
Join the Entrepreneurial Tribe!
Aditya Birla Money Limited
Symbol : APLLTD | BSE Code : 533573 | Sector : PHARMACEUTICALS - INDIAN - BULK DRUGS & FORMLN
Market Cap (₹ Cr.)
Turnover (₹ Cr.)
14/05/2026 BSE 0.05(0.01)Close Price: ₹ 768.40 Volume: 3,647.00
14/05/2026 BSE -20.40(-2.59)Close Price: ₹ 768.35 Volume: 7,695.00
14/05/2026 BSE 3.35(0.43)Close Price: ₹ 788.75 Volume: 10,790.00
14/05/2026 BSE 8.05(1.04)Close Price: ₹ 785.40 Volume: 14,642.00
14/05/2026 BSE -8.30(-1.06)Close Price: ₹ 777.35 Volume: 5,862.00
No Data Available
Alembic Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 15 May 2026.
Alembic Pharmaceuticals to discuss results & dividend
Alembic Pharmaceuticals receives USFDA approval for Fingolimod Capsules
Alembic Pharma gains after incorporating subsidiary in Philippines
In Cr.
Alembic Pharmaceuticals Limited manufactures and markets generic pharmaceutical products all over the world. The company's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. The company is one of the leaders in branded generics in India. Alembic Pharmaceuticals Limited was incorporated on June 16, 2010 as a wholly owned subsidiary of Alembic Limited. The company is engaged in pharmaceuticals business. As per the Scheme of Arrangement, the 'Pharmaceutical Undertaking' of Alembic Limited got demerged and transferred to the Company with effect from April 1, 2010. In April 2011, the company ceased to be a subsidiary of Alembic Ltd consequent to the allotment of 13,35,15,914 equity shares of Rs 2 each to the shareholders of Alembic Ltd as per the scheme of arrangement. The shareholding of Alembic Ltd in the company reduced from 100% to 29.18%. Thus, the company became an associate of Alembic Ltd.In September 2011, the equity shares of the company were listed on the Bombay Stock Exchange and National Stock Exchange. During 2012, Alembic and Breckenridge Announced Paragraph IV ANDA Litigation with Pfizer on Desvenlafaxine (Pristiq). The company enters into a product development and license agreement with Accu-Break Pharmaceuticals, Inc, USA. During 2013, the company got USFDA approval for its NDA - Desvenlafaxine Base Extended Release Tablets and also entered into an out-licensing agreement with Ranbaxy Pharmaceuticals Inc (Ranbaxy) to market its product in USA. During 2014, the company announces joint venture with Adwiya Mami SARL Algeria through its wholly owned Subsidiary - Alembic Global Holding S.A.'.During 2015, the company's associate signs exclusive agreement with Novartis. During the year, the company launched Aripiprazole on Day-1. Also during the year, the company transitioned to own marketing in the US.In 2016, the company formed 60:40 jo